最近資訊：
DPP4-I 類的糖尿病治藥物Saxagliptin 與 Alogliptin 需注意其心血管併發症。
FDA 要求Saxagliptin 加上，會增加27%心衰竭的危險性。
Alogliptin則會增加19%心衰竭。
參考文獻：
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; DOI:10.1056/NEJMoa1307684.
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; DOI:10.1056/NEJMoa1305889.
1. Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus —Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53 or SAVOR)
2. Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE)
Search